-+ 0.00%
-+ 0.00%
-+ 0.00%

MacroGenics sells capped Zynyz royalty interest to Sagard for $60 million

PUBT·05/04/2026 11:36:29
Listen to the news
MacroGenics sells capped Zynyz royalty interest to Sagard for $60 million
  • MacroGenics entered expanded royalty purchase agreement with Sagard Healthcare Partners, selling capped royalty interest on future global net sales of ZYNYZ in exchange for cash.
  • Transaction delivers USD 60 million upfront payment, with eligibility for additional 2026 sales-based milestone of up to USD 20 million tied to sale of royalty rights.
  • Royalty rights revert to MacroGenics once Sagard receives total payments equal to 1.7x its investment by Sept. 30, 2032, or 2x its investment at any time thereafter.
  • ZYNYZ is PD-1 inhibitor licensed to Incyte under 2017 global collaboration; Incyte markets drug in US.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.